Clinical trial data have generated significant interest in retatrutide because of its substantial weight-loss results, including Phase 3 findings showing average body weight reductions of more than 30% at the highest studied dose over 80 weeks
However, we dont yet have studies available that directly compare the two versions
If cost, side effects, or maintenance dosing is the concern, dosing should be individualized with the prescribing clinician
Hierdoor kan een deel van het verloren gewicht terugkomen wanneer gezonde leefstijlgewoonten niet worden voortgezet
Insulin secretion becomes more glucose-dependent rather than basal, reducing the risk of hypoglycemia while simultaneously improving postprandial glucose control
These are trial-based exclusions and do not constitute established contraindications prior to MHRA authorisation: A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Severe gastrointestinal disorders such as gastroparesis Pregnancy or breastfeeding Significant renal or hepatic impairment (pending further safety data) UK patients interested in accessing retatrutide through a clinical trial should speak with their GP or a specialist obesity service
